Abstract
Background: S-1 plus oxaliplatin (SOX) was approval for gastric cancer (GC) at 2014. Paclitaxel (PTX) containing regimen (PCR) is one of the standard therapy of second line. The peripheral neuropathy is known as common toxicity with PCR and oxaliplatin. So, we evaluated the peripheral neuropathy with PCR as second line after oxalipatin containing regimen (OCR) and S-1 plus cisplatin (SP).Methods: Between January 2010 and April 2013, the pts who received PCR after OCR (SOX and SOX plus leucovorin) and SP were examined retrospectively. The adverse events and efficacy were investigated.Results: Among 39 pts who received PCR as second line, 14 pts were administered OCR and 25 pts were administered SP as first line. The peripheral neuropathy (grade 0/1/2) after first line was 50/50/0% in OCR group and 80/20/0% in SP group. The rates of weekly PTX/ nab-PTX were 73.1/ 26.9% in OCR group and 92.9/ 7.1% in SP group. The median cycle of PCR was 5 (2-11) in OCR group and 3 (2-13) in SP group. The median progression-free survival was 4.2 (95%CI: 2.7-6.7) months in OCR group and 3.1 (95%CI: 2.6-4.5) months in SP group. The peripheral neuropathy (all grade/ grade3-4) was observed as follows; OCR group, 71.4/ 21.4%; SP group, 69.2/ 7.6%. Only one pt in SP group withdrew from PCR because of peripheral neuropathy.Conclusion: Althouh the present study is retrospective, OCR as first line might increase severe peripheral neuropathy with PCR as second line. Background: S-1 plus oxaliplatin (SOX) was approval for gastric cancer (GC) at 2014. Paclitaxel (PTX) containing regimen (PCR) is one of the standard therapy of second line. The peripheral neuropathy is known as common toxicity with PCR and oxaliplatin. So, we evaluated the peripheral neuropathy with PCR as second line after oxalipatin containing regimen (OCR) and S-1 plus cisplatin (SP). Methods: Between January 2010 and April 2013, the pts who received PCR after OCR (SOX and SOX plus leucovorin) and SP were examined retrospectively. The adverse events and efficacy were investigated. Results: Among 39 pts who received PCR as second line, 14 pts were administered OCR and 25 pts were administered SP as first line. The peripheral neuropathy (grade 0/1/2) after first line was 50/50/0% in OCR group and 80/20/0% in SP group. The rates of weekly PTX/ nab-PTX were 73.1/ 26.9% in OCR group and 92.9/ 7.1% in SP group. The median cycle of PCR was 5 (2-11) in OCR group and 3 (2-13) in SP group. The median progression-free survival was 4.2 (95%CI: 2.7-6.7) months in OCR group and 3.1 (95%CI: 2.6-4.5) months in SP group. The peripheral neuropathy (all grade/ grade3-4) was observed as follows; OCR group, 71.4/ 21.4%; SP group, 69.2/ 7.6%. Only one pt in SP group withdrew from PCR because of peripheral neuropathy. Conclusion: Althouh the present study is retrospective, OCR as first line might increase severe peripheral neuropathy with PCR as second line.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
